A recently published study on novel malaria vaccines features Attana’s technology
A recent study published in Nature Communications enables a novel design of second-generation placental malaria vaccines. Attana’s technology played a vital role in the research and the study’s discoveries.
Plasmodium falciparum is the most lethal human malaria parasite causing placental malaria. It is well-known that pregnant women have a higher risk of being infected and placental malaria is estimated to result in 900,000 low birth weight deliveries each year in Africa alone. However, after exposure to malaria during pregnancy, women develop antibodies against VAR2CSA, a plasmodium falciparum protein. Therefore, VAR2CSA is utilized in the development of vaccines protecting pregnant women.
The discovery enables the development of more effective malaria vaccines
In a recent study published in Nature Communications, a team from the University of Copenhagen, present their discoveries on the VAR2CSA protein’s structure and its interactions with the glycosaminoglycan chondroitin sulfate A (CS). Their observations enable the design of new VAR2CSA-based placental malaria vaccines, providing hope for a vaccine eliciting a broadly reactive, parasite binding inhibiting antibodies.
Attana’s contribution
Throughout the research process the researchers have used Attana’s CellTM 250 biosensor technology for kinetic analysis of the VAR2CSA binding to glycosaminoglycan chondroitin sulfate (CS). Attana is proud to have been able to contribute to this important topic of study and look forward to future collaborations and discoveries.
The entire study can be found here.
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: